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Results Epithelial ovarian cancer tissues showed a 
decrease in TGF-β1 I receptor (p < 0.05) and a change in 
Smad2/3 protein levels. Additionally, after treatment of 
cell lines with DHT, protein levels of TGF-β1 receptors 
(TGFBR1–TGFBR2) showed a decrease (p < 0.05) that 
might cause a potential disorder in TGF-β1 response, rep-
resented by the significant decrease in p21 protein levels in 
the presence of DHT (p < 0.001).
Conclusions Overall, our results indicate a defect in the 
canonical TGF-β signaling pathway in epithelial ovarian 
cancer caused by androgen action, thus suggesting eventual 
changes in such tissue proliferation rates.
Keywords Epithelial ovarian cancer · Androgen 
receptor · TGF-β signaling pathway
Introduction
Epithelial ovarian cancer (EOC) accounts for 85–95 % of 
ovarian malignant neoplasms (Auersperg 2013). Epithelial 
ovarian cancer represents the second cause of gynecologi-
cal death following uterine cervix cancer. According to a 
recent FIGO report, EOC is the seventh most common dis-
ease among women worldwide (Prat 2007). Among the fea-
tures of EOC are a silent evolution, a late detection, a poor 
response to therapy and a high angiogenic potential. Con-
sequently, women with EOC have a low survival rate (Jor-
dan et al. 2006; Auersperg et al. 2002). The pathogenesis of 
ovarian carcinoma is somewhat unclear, and several mecha-
nisms have been suggested to explain the etiology of such 
disease (Lukanova and Kaaks 2005). In such context, among 
the hypotheses attempting to explain its origin, there is one 
related to steroid hormones, proposing that excess stimula-
tion of ovarian surface epithelium with androgens might 
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increase cancer risk (Risch 1998). With regard to andro-
gens and EOC, studies explain that androgens and other sex 
steroids have a significant role in ovarian carcinogenesis 
(Schock et al. 2014; Ligr et al. 2011; Olsen et al. 2008). To 
elucidate the molecular mechanism underlying the involve-
ment of androgens in ovarian carcinogenesis, studies have 
linked the androgen signaling pathway with molecules such 
as the transforming growth factor beta 1 (TGF-β1) (Li and 
Karlan 2008). TGF-β1 is a member of a cytokine family 
known as a potent cell growth inhibitor. It also participates 
in a variety of cell processes such as cell proliferation, mor-
phogenesis, migration and apoptosis (Antony et al. 2010; 
Siegel and Massagué 2003). The canonical TGF-β1 sign-
aling pathway starts when the ligand (TGF-β1) binds the 
TGF-β1 II receptor (TGFBR2) that in turn recruits TGF-β1 
I receptor (TGFBR1) creating a complex. TGFBR2 phos-
phorylates TGFBR1 at the GS domain, thus enabling its 
activation. Once TGFBR1 becomes activated, such recep-
tor phosphorylates R-Smad (Smad2 and 3). Phosphoryla-
tion of Smad2/3 enables the creation of dimers or trimers 
with a co-Smad, Smad4. Such complex is translocated to 
the nucleus and interacts with the DNA-binding domain, 
recruiting co-activators or co-repressors to modulate gene 
transcription (Siegel and Massagué 2003). The TGF-β1 
signaling pathway (Smad2, 3 and 4) is involved in the regu-
lation of tissue homeostasis and is responsible for transcrip-
tional activation of p21Cip1, p15INK4B and c-myc genes. 
The first two encode the cell cycle inhibitors p21 and p15, 
while c-myc is a transcriptional repressor (Massague and 
Gomis 2006). Studies on prostate cancer have demonstrated 
androgenic control in TGF-β1 signaling through suppression 
of TGFBR2 transcription suppression (Song et al. 2008). 
Another study, on prostate epithelial cells, showed that 
androgens such as DHT may generate a downregulation of 
Smad3 (Song et al. 2010). On the other hand, a relationship 
between the androgen receptor (AR) and TGF-β1 receptor 
expression has been demonstrated in ovarian cancer (Evan-
gelou et al. 2000); however, the underlying mechanism is 
incompletely understood. Moreover, how such association 
might affect the levels of some molecules involved in pro-
liferation remains unclear. Based on the fact that androgens 
play an important role in the development of ovarian cancer 
(Gibson et al. 2014), the purpose of the present study was 
to assess the role of androgen receptors and the androgen 
DHT on the canonical TGF-β1 signaling pathway through 
the assessment of a possible effect on molecules involved in 
proliferation such as the p21 protein.
Materials and methods
The present research was approved by the Ethics Commit-
tee of the Hospital Clínico de la Universidad de Chile and 
by the Ethics Committee of the Escuela de Medicina de la 
Universidad de Chile. All study subjects provided a written 
informed consent.
Human tissue specimens
Human ovarian specimens were obtained from fourteen 
(14) patients as follows: normal ovary samples (inactive 
ovaries, I-Ov) were obtained from women with a non-ovar-
ian pathological condition (n = 7), and another specimen 
group consisted from samples obtained by women with a 
diagnosis of serous EOC (n = 7).
An experienced pathologist performed histopathological 
analysis and classification of samples. All the subjects par-
ticipating in the study were perimenopausal or postmeno-
pausal women, aged between 46 and 68.
Immunohistochemistry
Immunostains for AR, TGF-β1, TGFBR1, TGFBR2, 
pSmad2 and pSmad3 were performed on 5-mm sections 
of paraffin-embedded ovarian tissue biopsies. Tissue sec-
tions were deparaffinized in xylene and hydrated in serial 
grading of alcohol solutions. Sections were incubated in 
an antigen recovery solution (sodium citrate buffer 10 
mMol/L, pH 6.0) at 96–98 °C for 20 min. The endog-
enous peroxidase activity was blocked through incubation 
of the samples in hydrogen peroxide 3 % (v/v) for 15 min. 
Non-specific antibody binding was prevented with a spe-
cific blocker of the Histostain SP kit (Zymed Laboratories, 
San Francisco, CA, USA). Samples were incubated over-
night at 4 °C with the primary antibody (Table 1). Nega-
tive controls were performed on adjacent sections and were 
incubated without the primary antibody, as well as with 
specific antisera of the non-immune species. The second-
ary antibody was a biotinylated anti-mouse/anti-rabbit 
immunoglobulin. The reaction was developed through the 
use of streptavidin–peroxidase system using 3,3′-diamin-
obenzidine as chromogen. Counterstaining was done with 
hematoxylin. Slides were analyzed under an optical Olym-
pus BX51 microscope (Olympus Corporation, Tokyo, 
Table 1  Antibody and dilutions used in immunohistochemistry and 
immunocytochemistry
Antibody Dilution Supplier Type
AR 1:300 Abcam Rabbit polyclonal
TGF-β1 1:300 Abcam Rabbit polyclonal
TGFBR1 1:200 Abcam Rabbit polyclonal
TGFBR2 1:250 Abcam Rabbit polyclonal
pSmad2 1:200 Abcam Rabbit polyclonal
pSmad3 1:200 Abcam Rabbit polyclonal
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Japan). Images were acquired with a Micro-editor 3.3 RTV 
camera (Q Imaging, Surrey, BC, Canada). Immunohisto-
chemical assessment of each protein was performed with 
a semiquantitative method previously described for endo-
metrial tissue (Rivero et al. 2012). With the Image-Pro 
Plus® acquisition system, images were acquired in 1000× 
resolution and processed in TIFF format. Analysis was per-
formed through the measurement of positive pixel intensity 
per area using the semiquantitative integrated optical den-
sity tool (IOD) in the Image-Pro Plus 6.2 program (Media 
Cybernetics Inc., Silver Spring, MD, USA). IOD assess-
ment was done randomly in different regions of the epithe-
lium in each specimen. Data are presented as IOD arbitrary 
units (AU). The means of the values obtained per sample 
and per study group were expressed as mean ± SEM.
Cell lines and cell culture
Normal human ovarian superficial epithelial cells (HOSE) 
obtained from a postmenopausal patient with endome-
trial cancer were immortalized with SV40-Tag. Con-
versely, A2780 is a drug-sensitive human ovarian cancer 
cell line with epithelial morphology that was established 
from tumor tissue of a patient before treatment. Both cell 
lines were cultured in DMEM-Ham/F12 medium (Sigma-
Aldrich Co. St Louis, MO, USA) in the presence of peni-
cillin G 100 IU/mL, streptomycin sulfate 100 mg/mL and 
amphotericin B with 10 % bovine serum treated with char-
coal/dextrane (Hyclone™ Thermo Fisher Scientific, Roch-
ester, NY, USA) until culture reached 80 % confluence, as 
previously described (Tapia et al. 2011).
Cell culture treatment
Cells were washed twice in Dulbecco’s phosphate-buffered 
saline (DPBS, GIBCO® Invitrogen Corporation, Camarillo, 
CA, USA) and cultured in serum-free medium with 0, 10 
and 100 nmol/L DHT (Sigma-Aldrich Co, St Louis, MO, 
USA) during 72 h and with 10 ng/mL TGF-β1 (Abcam, 
Cambridge, MA, EE.UU.). In some experiments, cells were 
treated with DHT plus TGF-β1.
Immunocytochemistry
HOSE and A2780 cells were fixed with 4 % paraformal-
dehyde during 15 min at room temperature. Endogenous 
peroxidase activity was blocked with sample incubation 
in hydrogen peroxide 3 % (v/v) during 15 min. Cells were 
washed and subsequently incubated with skim milk for 
10 min at room temperature to block non-specific bind-
ing and were incubated overnight at 4 °C with the pri-
mary antibody against AR, TGF-β1, TGFBR1, TGFBR2, 
pSmad2, pSmad3 and p21. Subsequently, cells were 
washed and incubated with the secondary antibody (KPL, 
Kirkegaard & Perry Laboratories Inc, MD, USA) during 
30 min at 37 °C. Cells were incubated during 1 min at 
room temperature with the 3,3′-diaminobenzidine liquid 
substrate (DAB) (DakoCytomation, Inc., CA, USA), and 
hematoxylin was used for counterstaining (Lerner Labora-
tories, Pittsburgh, PA, USA). Slides were analyzed using 
an Olympus BX51 optical microscope (Olympus Corpo-
ration, Tokyo, Japan). A Micro-editor 3.3 RTV camera (Q 
Imaging, Surrey, BC, Canada) was used for image acqui-
sition. Each slide was analyzed using the measurement of 
positive pixel intensity by means of the integrated opti-
cal density semiquantitative analysis tool (IOD) in the 6,2 
Image-Pro Plus program (Media Cybernetics Inc., Silver 
Spring, MD, USA). Data on p21 were expressed as posi-
tive cell percentage. Three independent observers carried 
out the analysis, and positive stain was assessed in at least 
1000 cells per sample.
Protein extraction and Western blotting
Cell cultures (roughly 106 cells) underwent homogenization 
in a lysis buffer (Tris 50 mM, NaCl 150 mM, DOT 0.5 %, 
Triton 1 %, SDS 0.1 %). After spinning at 15,000×g for 
20 min, protein concentrations were quantified with the BCA 
protein assay kit (Pierce, Rockford, IL, USA). Subsequently, 
40 g of protein was denatured and underwent fractionation in 
SDS-PAGE, to be finally transferred to a nitrocellulose mem-
brane. After blocking with 10 % skim milk, membranes were 
incubated overnight with the primary antibody (TGFBR1 
and TGFBR2) in TBST solution at 4 °C. After washing, 
membranes were incubated for 60 min at room tempera-
ture with a species-specific peroxidase-conjugated anti-rab-
bit IgG (KPL, Kirkegaard & Perry Laboratories Inc, MD, 
USA) at a 1:5000 dilution. After washing, bound antibodies 
were detected with an enhanced chemiluminescence system 
(Amersham Biosciences, Piscataway, NJ, USA). Then, mem-
branes were stripped, washed and blocked. Subsequently, 
they were incubated with anti-GAPDH (Sigma-Aldrich 
Co, St Louis, MO, USA) at a 1:15,000 dilution during 1 h, 
washed and incubated with anti-mouse antibody (Abcam, 
Cambridge, MA, USA) at a 1:5,000 dilution for 30 min. At 
the end, bound antibodies were detected with chemilumi-
nescence. Protein band intensities were quantified with the 
UN-SCAN-IT Automated Digitizing System Software ver-
sion 5.1. Results were expressed as arbitrary units (AU). The 
means of values obtained per sample and per study group 
were expressed as mean ± SEM.
Small‑interference RNA constructs and transfection
Sequences used against human AR (GenBank adhesion no. 
NM_000044) were used in a prior study (Cai et al. 2011). 
50 J Cancer Res Clin Oncol (2016) 142:47–58
1 3
Specifically, the sequence used for AR was 5′-ACCGAGGAG 
CUUUCCAGAAUCUGUU-3′. A non-specific control small-
interference RNA (siRNA) (5′-CCAUGGCGCCAAUUCCA 
AACAGUUU-3′) was included in all the experiments. All 
transfections were carried out using siRNA Lipofectamine 
2000 (Invitrogen) as per manufacturer’s instructions. Briefly, 
500,000 A2780 cells were seeded in phenol red-free DMEM-
Ham F12 medium containing 2 % bovine saline without anti-
biotics. Twenty-four (24) hours later, when cells were attached 
to the plate, they were transfected with siRNA (100 pmol) 
using 5 μL of Lipofectamine 2000 in a total volume of 1 mL 
of OPTI-MEM medium (Invitrogen) per well. Six (6) hours 
after transfection, transfection reagents were removed and 
cells were treated as indicated in each experiment. Western 
blotting was used to verify AR knockdown.
RNA isolation and semiquantitative RT‑PCR
Total RNA was isolated from A2780 cell line using TRI-
zol® reagent as per manufacturer’s instructions. Quanti-
tation of RNA was carried out with spectrophotometry 
(A260:A280), while RNA integrity was determined by 
denaturing agarose–formaldehyde gel electrophoresis. 
RNA was visualized by adding GelRed™ to the sample 
before loading on the gel. RNA was stored at −80 °C until 
used. Two micrograms (2 μg) of total RNA was digested 
with DNase I and was transcribed to cDNA through RT 
with M-MLV RT using random primers in a total volume of 
25 mL. Amplifications were obtained through PCR using 
gene-specific primers (Table 2). GAPDH was used as an 
internal control. Semiquantitative RT-PCRs were achieved 
in the exponential linear zone amplification for each gene 
studied. PCR conditions for each gene were 2 mmol/L 
MgCl2, 0.20 mmol/L dNTPs, 2 U Taq DNA polymerase 
and 30 pmol of each primer. PCR amplification was carried 
out in a PTC-100 thermocycler (MJ Research Inc., Water-
town, MA, USA) and a Mastercycler Personal (Eppendorf 
AG, Foster City, CA, USA). Resolution of PCR products 
was carried out on 2 % agarose gel electrophoresis with 
subsequent staining with GelRed™. Bands were analyzed 
with a UN-SCAN-IT gel 4.1 image analyzer (Silk Scien-
tific Corporation) and normalized by GAPDH. Results 
were expressed in arbitrary units (AU). The means of 
the values obtained per sample and per study group were 
expressed as mean ± SEM.
Statistical analysis
The number of ovarian tissue samples (n = 7 for each study 
group) was determined assuming 5 % probability of type 
1 error and 20 % probability of type 2 error. Differences 
between groups were analyzed through the Kruskal–Wallis 
test and the Dunn’s post-test. All p values under 0.05 were 
considered significant.
Results
Protein levels of AR and molecules of the TGF-β1 signal-
ing pathway in ovarian epithelial tissue.
The presence of AR was analyzed in I-Ov and poorly 
differentiated EOC specimens. Positive immunodetection 
was assessed for such protein in both tissue types (Fig. 1). 
A weak staining was observed for AR in the nuclei and 
the cytoplasm of epithelial cells of ovarian tissues I-Ov, 
while nuclear and cytoplasmic staining for AR was strong 
in EOC tissues (Fig. 1a). The semiquantitative analysis of 
AR protein levels showed a significant increase in this pro-
tein in EOC tissues as compared to I-Ov tissues (p < 0.001) 
(Fig. 1b).
Furthermore, the presence of TGF-β, its receptors 
(TGFBR1—TGFBR2) and Smad2/3 proteins in their phos-
phorylated status was analyzed in ovarian tissue. There 
were no differences in TGF-β1 immunodetection between 
both study groups. However, TGFBR1 showed a homoge-
neous cytoplasmic staining in I-Ov tissues, while in contra-
position, TGFBR1 detection was weak in the cytoplasmic 
compartment of EOC samples (Fig. 1a). The semiquanti-
tative analysis (IOD-AU) evidenced a significant decrease 
in positive staining for such receptor in EOC as compared 
to control tissues (p < 0.05) (Fig. 1b). On the other hand, 
Table 2  Gene sequence and PCR products
Gene Sequence bp
TGFBR1 5′ GGT CTT GCC CAT CTT CAC AT 3′
5′ TCT GTG GCT GAA TCA TGT CT 3′
155
TGFBR2 5′ GTC TAC TCC ATG GCT CGT GT 3′
5′ ATC TGG ATG CCC TGG TGG TT 3′
197
AR 5′ AGA TGG GCT TGA CTT CAG AAA G 3′
5′ ATG GCT ATT CAG TAC TCC TGG A 3′
545
GAPDH 5′ GAG TCA ACG GAT TTG GTC GT 3′
5′ ATC CAC AGT CTT CTG GGT G 3′
548
GAPDH 5′ CCA CCA TGG AGA AGG CTG GG 3′
5′ ATC ACG CCA CAG TTT CCC GG 3′
287
Fig. 1  Immunodetection and semiquantitative analysis of AR, TGF-
β1, its receptors (TGFBR1 and TGFBR2), pSmad2 and pSmad3 in 
ovarian tissue. In a detection for AR, TGF-β1, TGFBR1, TGFBR2, 
pSmad2 (Ser467), pSmad3 (Ser423 + Ser425) proteins in paraffin 
wax section of I-Ov tissue (right panel) and EOC tissue (left panel), 
n = 7 for each study group. Positive staining for each antigen (brown 
color) was detected in epithelial compartment of all studied ovar-
ian samples. As a negative control, the primary antibody was omit-
ted. b Represents the semiquantitative analysis. Immunostaining was 
expressed as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001. 
Scale bar represents 50 μm
▸
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when analyzing TGFBR2 levels, detection was positive in 
both studied ovarian tissue types, and the semiquantitative 
analysis evidenced a significant increase in TGFBR2 in 
EOC samples (p < 0.05) (Fig. 1b).
Other critical molecules implicated in TGF-β1 signal-
ing pathway are the Smad proteins that are activated fol-
lowing phosphorylation. Immunohistochemical analysis 
was carried out for phosphorylated Smad2 and Smad3 with 
antibodies against their specific sites of phosphorylation by 
TGF-β1 receptor. Thus, Smad2 phosphorylation in Ser467 
(pSmad2) and Smad3 phosphorylation in Ser423 + Ser425 
(pSmad3) were analyzed. Figure 1a shows positive immu-
nodetection for both proteins in I-Ov and EOC tissues. 
Both cytoplasmic and nuclear staining was observed for 
pSmad2 in I-Ov tissues, while staining was mainly cyto-
plasmic in EOC tissues. A significant increase in pSmad2 
was found in EOC tissues as compared to I-Ov tissues 
(p < 0.05) (Fig. 1b). The pSmad3 protein was observed in 
both study tissues, showing a strong nuclear staining. The 
semiquantitative analysis did not show differences between 
I-Ov and EOC tissues (Fig. 1b). All together, the results 
herein show that the TGF-β1 signaling pathway is altered, 
suggesting changes in cell cycle control in EOC tissues.
Protein levels of AR, TGF-β1 and molecules of the 
TGF-β1 signaling pathway in ovarian epithelial cells.
To address this objective, cellular location of TGF-β1 
and its receptors was analyzed through immunocytochem-
istry (Fig. 2c, d). Androgen receptor levels were assessed 
through Western blot (Fig. 2a, b). A filamentous staining of 
TGF-β1 was observed in HOSE and A2780 cells. In HOSE 
cells, TGF-β1 immunostaining was homogeneous, while 
in A2780 cells, it was heterogeneous, and some cells were 
more strongly stained than others (Fig. 2c). Furthermore, 
AR protein levels were significantly lower in HOSE cells 
as compared to A2780 cells (p < 0.05) (Fig. 2a, b).
Cellular location of TGFBR1, TGFBR2 and Smad2/3 
proteins was assessed in HOSE and A2780 cells (Fig. 2c). 
For TGFBR1, a strong granular cytoplasmic staining was 
detected in HOSE cells, while staining was weak in A2780 
cells, thus evidencing a significant decrease in TGFBR1 
levels in A2780 cells, as compared to HOSE cells (Fig. 2d). 
The presence of TGFBR2 was detected in both cell lines; 
however, there were no differences in TGFBR2 levels 
between HOSE and A2780 cells (Fig. 2d).
Smad proteins were also analyzed in the study cell lines 
(Fig. 2b). Positive immunodetection for pSmad2 was evi-
denced in both cell lines. Protein levels of pSmad2 were 
higher in A2780 cells. Conversely, staining for pSmad3 
was mainly nuclear and significantly higher in A2780 cells, 
as compared to HOSE cells (p < 0.05) (Fig. 2c, d). Such 
results correlate adequately with the results obtained from 
ovarian tissue specimens in I-Ov and EOC, thus suggesting 
that HOSE and A2780 cell lines constitute a representative 
in vitro model to study epithelial ovarian cancer.
Effect of DHT on mRNA levels and TGFBR1 
and TGFBR2 protein levels on HOSE and A2780 cell 
lines
Because TGFBR1 and TGFBR2 activation is important 
in TGF-β1 signaling pathway, we assessed whether such 
receptor levels underwent changes as a result of different 
DHT doses and different exposure times. Both TGF-β1 
receptors were analyzed in A2780 cells after treatment of 
10 and 100 nmol/L DHT during 48 h. No differences were 
detected in TGFBR1 and TGFBR2 mRNA and protein lev-
els (data not shown). Moreover, when A2780 were treated 
with 100 nmol/L DHT during 72 h, a significant decrease 
in TGFBR2 mRNA levels was observed, as compared 
to the control condition (control = 1.1 ± 0.0; 10 nmol/L 
DHT = 0.9 ± 0.017; 100 nmol/L DHT = 0.87 ± 0.01 
*; * p < 0.05 vs. control); there were no differences 
between study groups in TGFBR1 mRNA levels (con-
trol = 1.0 ± 0.0; 10 nmol/L DHT = 0.95 ± 0.06; 
100 nmol/L DHT = 0.87 ± 0.03; p = 0.11). However, a 
significant decrease in TGFBR1 (Fig. 3b) and TGFBR2 
(Fig. 3d) protein levels was observed in A2780 cells treated 
with 100 nmol/L DHT (p < 0.05). Contrariwise, treat-
ment with DHT did not have any effect on HOSE cells 
(Fig. 3a–c).
A siRNA against AR was used to assess whether the 
decrease in TGFBR1 and TGFBR2 protein levels in A2780 
cells was an effect of the AR-DHT complex. The AR 
siRNA reduced AR protein levels in 45 % (Fig. 3f), in turn, 
non-specific siRNA (n-siRNA) did not modify AR levels 
(control = 1 ± 0.0; n-siRNA = 1.07 ± 0.01; p = 0.08). 
Whether AR silencing was maintained during the 72 h of 
stimulation was also assessed (Fig. 3e). Between 48 and 
72 h, AR levels underwent knockdown, while at the fifth 
day, AR mRNA levels were recovered (Fig. 3e). Then, 
A2780 transfected cells with and without AR siRNA were 
Fig. 2  Immunodetection and semiquantitative analysis of AR, TGF-
β1, its receptors (TGFBR1 and TGFBR2) and pSmad2 and pSmad3 
in ovarian cell lines. a Western blotting analysis was performed for 
AR in cell lines, and equal amount of total protein for HOSE and 
A2780 cell lines was loaded in each lane. Protein AR was detected as 
bands with molecular mass of 110 kDa; b represents the semiquanti-
tative analysis of three independent experiments for AR in arbitrary 
units (AU); c detection for TGF-β1, TGFBR1, TGFBR2, pSmad2 
(Ser467), pSmad3 (Ser423 + Ser425) proteins in HOSE and A2780 
cell lines. As a negative control, the primary antibody was omitted; 
d represents the semiquantitative analysis; 1000 cells were analyzed 
for each molecule in three independent experiments. Immunostaining 
was expressed as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001. 
Scale bar represents 20 μm
▸
53J Cancer Res Clin Oncol (2016) 142:47–58 
1 3
54 J Cancer Res Clin Oncol (2016) 142:47–58
1 3
Fig. 3  Effect of DHT on TGFBR1 and TGFBR2 protein lev-
els in HOSE and A2780 cells. Cell cultures were exposed to 10 or 
100 nmol/L DHT for 72 h; in addition, A2780 cells were treated with 
or without AR siRNA. As control, red phenol-free culture medium 
was used. Immunoblot and semiquantitative analysis of TGFBR1 in 
HOSE and A2780 cells (a and b, respectively) detected as a band 
with a molecular mass of 58 kDa. Immunoblot and semiquantitative 
analysis of TGFBR2 in HOSE and A2780 cells (c and d, respectively) 
detected as a band at 63 kDa. Conventional RT-PCR in different 
hours (e) and Western blotting analysis with different amounts of AR 
siRNA (f) were performed for AR. Band intensities were quantified 
by scanning densitometry and normalized to intensities observed for 
GAPDH (37 kDa) as internal control. The data from five independent 
experiments were expressed as mean of fold change respect to con-
trol ± SEM. a <0.05 100 nmol/L versus control; b <0.05 100 nmol/L 
versus AR siRNA; c <0.05 10 nmol/L versus AR siRNA
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treated with 10 and 100 nmol/L DHT to analyze TGFBR1 
and TGFBR2 protein levels. A decrease in TGFBR1 and 
TGFBR2 protein levels was evidenced with DHT; however, 
in the presence of the AR siRNA, receptor protein levels 
were similar to those of control conditions with 100 nmol/L 
DHT (Fig. 3b–d). These results indicate that the DHT-AR 
complex might be acting at the transcriptional or transla-
tional level and might cause, by this means, a decrease in 
TGFBR1 and TGFBR2 protein levels.
Effect of TGF‑β1 and DHT on p21 protein levels 
in ovarian epithelial cells
To assess whether the decrease in TGFBR1 and TGFBR2 
levels caused by DHT had an impact on the response of the 
TGF-β1 signaling pathway, levels of the cell cycle inhibitor 
p21 were studied in HOSE and A2780 cells after adminis-
tration of 10 ng/mL TGF-β1 and 100 nmol/L DHT during 
72 h (Fig. 4). Levels of p21 were analyzed with immuno-
cytochemistry, and the percentage of positive nuclei was 
obtained in HOSE and A2780 cells (Fig. 4a). There were no 
changes in the percentage of p21-positive nuclei in HOSE 
cells in presence of DHT as compared to control conditions 
(Fig. 4a, b). However, in the presence of TGF-β1, there 
was a significant increase in the percentage of p21-positive 
nuclei in HOSE cells (p < 0.05). Moreover, when such 
cells were treated with DHT plus TGF-β1, there were no 
differences as compared to controls (Fig. 4a, b). As for 
A2780 cells, in control conditions, there was a lower per-
centage of p21-positive nuclei as compared to HOSE cells 
Fig. 4  Immunodetection and semiquantitative analysis of p21 pro-
tein levels in ovarian cell lines. HOSE and A2780 cell lines were 
treated for 72 h with 100 nmol/L DHT, 10 ng/mL TGF-β1 and DHT 
plus TGF-β1 and controls with only culture medium. a Shows a rep-
resentative microphotography, where positive staining (brown color) 
was detected in the nuclei. The semiquantitative analysis is presented 
in b for HOSE cell line and c for A2780 cell line. Immunostaining 
was measured by the percentage of positive nuclei. The results were 
expressed as positive nuclei % ± SEM. *p < 0.05; ***p < 0.001. 
Scale bar represents 50 μm
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in the same conditions (Fig. 4a). In the presence of DHT, 
the percentage of p21-positive nuclei among A2780 cells 
decreased significantly (p < 0.001) as compared to A2780 
cell controls (Fig. 4a–c). On the other hand, in the pres-
ence of TGF-β1, the percentage of p21-positive nuclei did 
not increase as expected; p21 levels were similar to control 
conditions. Interestingly, there was a significant decrease 
in p21 as compared to control conditions (p < 0.05) when 
A2780 cells were treated with DHT plus TGF-β1 (Fig. 4a–
c). These results suggest that DHT might be disrupting the 
TGF-β1 signaling pathway, thus affecting p21 expression. 
Therefore, the latter might result in a modification of the 
cell cycle in epithelial ovarian cancer cells.
Discussion
In several pathological conditions, including cancer, there 
are defects in several growth factor signaling pathways, 
including TGF-β (Siegel and Massagué 2003; Vera et al. 
2014). The possible mechanisms that might be inhibiting 
the anti-proliferative action of TGF-β still remain unclear. 
In order to address this issue, the present research exam-
ined protein levels of the molecules implicated in the 
TGF-β signaling pathway such as TGF-β, its receptors and 
Smad2/3 proteins in tissues from patients with EOC and 
also in ovarian cell lines. Additionally, the possible role of 
androgens in TGF-β signaling pathway was analyzed. Our 
group and others (Elattar et al. 2012; Gibson et al. 2014) 
have demonstrated an increase in AR protein in EOC that 
in turn indicates a potential susceptibility of such tissue 
to androgen action, as it has been found in other tissues, 
such as the prostate (Zhou et al. 2015). Chipuk et al. (2002) 
described the interaction between androgens and the TGF-β 
signaling pathway. Through this interaction, androgens are 
able to block TGF-β response in epithelial cells of the pros-
tate. Such inhibition might be exerted through an associa-
tion between AR and Smad3, thus preventing the binding of 
Smad3 to Smad-binding elements (SBE) y, consequently, 
blocking the transcription of genes related to cell growth 
inhibition. According to our results, TGF-β1 protein levels 
were not modified either in EOC or in the studied cell lines, 
thus suggesting that the failure in cell cycle control might 
be at the downstream molecules of the TGF-β1 cascade, 
such as its receptors or Smad proteins. In this regard, the 
present work found a decrease in TGFBR1 protein levels 
in ovarian cancer tissue, thus suggesting that DHT might 
downregulate TGFBR1 protein levels but not the mRNA 
levels of this receptor. There is a little information about the 
androgens action in TGFBR1 levels regulation in other tis-
sues. Nevertheless, some studies have shown that TGFBR1 
expression may be regulated by the micro-RNA-141, 
among other micro-RNAs (Butz et al. 2012; Denby et al. 
2011). Additionally, other studies have shown that andro-
gens are able to regulate miR-141 levels (Tiryakioglu et al. 
2013; Waltering et al. 2011). Consequently, it is tempting to 
propose that the decrease in TGFBR1 that was found in the 
present study might represent a posttranscriptional effect of 
androgens, although more information is needed to estab-
lish such effect. On the other hand, we found an increase in 
TGFBR2 protein levels in ovarian cancer tissue, but not in 
the A2780 cell line. However, it is important to remember 
that the signaling pathway begins when TGF-β binds firstly 
to TGFBR2 that activates and recruits TGFBR1. This latter 
molecule is responsible for phosphorylation and activation 
of Smad proteins (Siegel and Massagué 2003). According 
to the results obtained in the present study, TGFBR1 was 
decreased in EOC tissues, suggesting that Smad protein 
activation and thus the response of the signaling pathway 
are impaired, and therefore, the increase in TGFBR2 that 
was found might be a compensatory effect of the tissue to 
balance the lack of response of such signaling pathway.
Discrepancies that were evidenced between the cell line 
and the tissue might also reside in the activation of other 
signaling pathways present in the tissue, in which TGFBR2 
might participate, such as MAPK activation and other 
Smad-independent signaling pathways implicated in the 
proliferation process (Derynck and Zhang 2003). Another 
important point to take into consideration is that TGBR2 
expression is also regulated by different micro-RNAs (Butz 
et al. 2012) that have not been fully analyzed in the ovary. 
Therefore, a study of these micro-RNAs in ovarian cancer 
might contribute to the understanding of the differences 
observed between the cell line and the tissue.
Also, treatment with DHT in A2780 cancer cell line 
resulted in a decrease in mRNA levels and in TGFBR2 pro-
tein levels, consistent with studies in other ovarian cell lines 
(Evangelou et al. 2000). The mechanism through which 
DHT acts is poorly understood. Some evidences in prostate 
cancer have demonstrated that androgens may downregu-
late TGFBR2 gene expression through a transcriptional 
mechanism in which DHT suppresses the binding of the 
transcription factor Sp1 to the TGFBR2 promoter. Levels 
of Smad3 mRNA could be reduced by the same mechanism 
(Song et al. 2008,  2010). In addition, other studies in pros-
tate cancer demonstrated that AR may regulate the decrease 
in TGFBR2 levels through micro-RNA-21 (Mishra et al. 
2014).
The other molecules of the TGF-β signaling pathway 
such as Smad proteins are also deregulated in EOC. An 
increase in Smad2 phosphorylation was detected in EOC; 
however, its cellular location was mainly cytoplasmic 
rather than nuclear. It has been stated that Smad protein 
build-up in the nucleus is closely related to TGF-β recep-
tor activity (Inman et al. 2002). Moreover, mutations in 
Smad2 have been described to cause a loss of affinity of 
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this protein for certain nucleoporins, with a concomitant 
failure in translocation of Smad2 toward the nucleus (Xu 
et al. 2002). On the other hand, increased phosphoryl-
ated Smad3 at a nuclear location in ovarian cancer cells 
observed in the present study, does not necessarily indicate 
that Smad3 could be involved in cell cycle inhibition. With 
regard to the latter, there are other phosphorylation sites 
for Smad3, the linker region, which may allow the activa-
tion of processes such as cell growth and invasion (Mat-
suzaki 2011). In fact, a study suggests that phosphoryla-
tion at the linker region of Smad3 does not affect either 
its activation by TGF-β or its translocation to the nucleus, 
but would affect the transcriptional activity of Smad3 and 
would block the expression of the inhibitor of the cell 
cycle such as p15 (Choi et al. 2013). Phosphorylation 
in this region could be induced by reactive oxygen spe-
cies (ROS) such as hydrogen peroxide (H2O2) that acti-
vates the Akt-ERK1/2-linker signaling pathway (Choi 
et al. 2013). In ovarian cancer, it has been demonstrated 
that growth factors such as EGF may induce the produc-
tion of H2O2 (Cheng et al. 2010), while in other cell types, 
it has also been observed that NGF can cause an increase 
in H2O2 production (Chiba et al. 2014). It is important to 
highlight that EGF and NGF are overexpressed in ovar-
ian cancer (Bartlett et al. 1996; Campos et al. 2007; Tapia 
et al. 2011). Therefore, it is possible to propound that in 
ovarian cancer, H2O2 might induce Smad3 phosphoryla-
tion at the linker region. Nevertheless, the mechanism 
should be confirmed in other studies.
Finally, to assess the response of the e TGF-β signaling 
pathway in ovarian cells, protein levels of the cell cycle 
inhibitor p21 were analyzed. Data of the present research 
reveal that under treatment with DHT, p21 protein levels 
decrease in ovarian cancer, suggesting a failure of TGF-
β1 response in ovarian cancer cells. As it is known, p21 
is a cyclin-dependent kinase protein (CDK), an inhibitor 
belonging to the Cip/Kip family of CDK inhibitors. Activa-
tion of p21 is crucial to cell cycle progression (Gartel and 
Radhakrishnan 2005). Several transcription factors such 
as Sp1/Sp3 (Gartel et al. 2001) regulate p21 levels. Sp1/
Sp3 transcription factors are regulated by DHT (Song et al. 
2008), thus indicating that a decrease in p21 protein levels 
may be a result of a direct effect of androgens or a con-
sequence of the failure of the TGF-β response due to an 
androgen-induced decrease in TGF-β receptors.
In conclusion, the present research evaluated the expres-
sion of molecules involved in the TGF-β-Smads signaling 
pathway and their association to androgens. The results 
obtained in EOC tissue and in the A2780 cell line, together 
with the studies of other authors carried out in other ovarian 
cell lines, suggest that the canonical TGF-β signaling path-
way might be altered in EOC where androgens may play 
an important role in downregulating receptor expression, 
particularly TGFBR1. The latter might be potentially 
involved in decreasing p21 levels. Additionally, andro-
gens may act directly on p21 expression by inducing their 
decrease. Such defects, among others, might contribute to 
epithelial proliferation in ovarian cancer, and their further 
study is necessary to elucidate the implicated mechanisms.
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